Seattle Genetics carries out research on cancer treatment drugs. Clay Siegall is the current president of the Seattle-Based biotechnology company.
Seattle Genetics is a fast growing cancer drug testing and research organization. Due to a large number of people suffering from cancer, the market for the drugs is big. The company is hiring more employees to help in the testing of the drugs to counter the market demand.
Adcentris is the most requested drugs owned by the Seattle. The drug has gone through over seventy trials to ascertain its effectiveness in the treatment of different types of lymphomas. Also, the company is conducting the clinical trials to test the possibility of the drug in treating previously untreated and newly diagnosed cancers. Seattle Genetics expects that Adcentris trials will have a significant impact on the company by the end of the year.
In the US and Canada, cases of lymphomas are high. Seattle Genetics realized significant returns from selling Adcentris in both countries in 2015. Furthermore, the company is expecting to make more money by the end of 2016 from the sale of the drug across US and Canada.
Seattle Genetics is making twelve more cancer treatment drugs apart from Adcentris. The drugs are still under clinical trials. The company is developing the medicine to combat other lymphomas that include breast and bladder cancers. Meantime, Seattle Genetics is researching on the new drugs. One of the additional drugs under scrutiny is the 33A. The purpose of carrying clinical test for the 33A is to establish its ability to treat myeloid leukemia.
To accomplish the medical testing and collect enough data on the drugs, Seattle is hiring additional employees. Apparently, the firm’s offices in the US and Switzerland require more staff. The company needs to employ staff to occupy their operations positions despite having over eight hundred workers.
The Seattle Genetics have many and big offices courtesy of their ambitious long-term goals. The company hires a hundred people annually for the past half a decade.
In conclusion, by hiring more employees to help in operations and collection of data on cancer drugs makes Seattle Genetics realize their goals.